Section 1: Introduction -- The Patient Who Stopped Because They Read Something

A 58-year-old man in Barbados has type 2 diabetes, hypertension, and a BMI of 31. He had a myocardial infarction three years ago and was discharged on atorvastatin 40 mg daily. He stopped it four months ago after reading an article on social media saying statins cause muscle damage, memory loss, and diabetes. He stopped without telling his doctor. His LDL-C at his last review was 4.1 mmol/L.

Statin non-adherence driven by media-amplified side effect concerns is one of the most prevalent and consequential treatment gaps in Caribbean cardiovascular care. The evidence for statins in secondary prevention -- after a myocardial infarction, stroke, or revascularisation procedure -- is among the strongest in all of clinical pharmacology. A patient with established cardiovascular disease who stops their statin is accepting a meaningfully higher risk of a second event.

Caribbean lipid management has four specific challenges:

Statin side effect fear and non-adherence. Online health misinformation about statins is widespread and disproportionately affects communities where trust in pharmaceutical medicine is low. Clinicians need a clear, evidence-based framework for addressing these concerns.

Rhabdomyolysis and myopathy interactions. The most clinically dangerous statin adverse effect is myopathy leading to rhabdomyolysis. This is not a class effect at standard doses -- it is an interaction-mediated effect, predominantly driven by CYP3A4 inhibition (Report 12). Understanding which statins are at risk and from which interactions allows the risk to be managed without abandoning statin therapy.

Cardiovascular risk assessment in the Caribbean context. Risk calculators derived from European or American populations may not accurately predict cardiovascular risk in Caribbean populations, who have distinct patterns of hypertension, diabetes, and metabolic disease.

The triglyceride and HDL pattern. Caribbean patients with metabolic syndrome and type 2 diabetes commonly present with a lipid pattern of elevated triglycerides, low HDL-C, and normal or mildly elevated LDL-C -- the atherogenic dyslipidaemia pattern that statins address less directly than LDL-predominant hypercholesterolaemia.

Section 2: Statin Pharmacology -- What They Do and How They Differ

2.1 Mechanism

Statins inhibit HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis. By reducing hepatic cholesterol production, they upregulate LDL receptors on hepatocyte surfaces, increasing LDL-C clearance from the plasma. They also have pleiotropic effects -- anti-inflammatory, plaque-stabilising -- that contribute to cardiovascular benefit independent of LDL-C reduction.

2.2 Potency comparison

Caribbean formulary note: Simvastatin and atorvastatin are the most widely available statins on Caribbean public sector formularies. Rosuvastatin is available privately in most territories. Pravastatin is available but less commonly used.

2.3 CYP3A4 and statin metabolism -- the interaction risk

Simvastatin, atorvastatin, and lovastatin are all CYP3A4 substrates. When CYP3A4 is inhibited, their plasma levels rise significantly -- the higher the statin level, the greater the myopathy risk.

Rosuvastatin and pravastatin are NOT CYP3A4 substrates. They carry substantially lower interaction-driven myopathy risk and should be considered when a patient requires a CYP3A4 inhibitor concurrently.

Section 3: Statin Side Effects -- Separating Evidence From Misinformation

3.1 Myopathy and rhabdomyolysis

Statin-associated muscle symptoms (SAMS) exist on a spectrum:

The critical distinction: Most patients who report muscle symptoms on statins have myalgia with normal CK. They do not have rhabdomyolysis, and the risk of stopping the statin (recurrent cardiovascular event) substantially outweighs the myalgia. The appropriate response is to check CK, consider a statin switch (to a lower-interaction drug), reduce dose, or switch dosing schedule (alternate-day dosing for rosuvastatin is an evidence-based option for patients with myalgia).

Rhabdomyolysis is almost always interaction-mediated. The following CYP3A4 inhibitors when combined with simvastatin or atorvastatin dramatically increase rhabdomyolysis risk:

Simvastatin 80 mg is no longer recommended due to its unacceptably high myopathy risk, particularly with any CYP3A4 inhibitor. Patients on simvastatin 80 mg should be reviewed and switched to an equivalent-efficacy dose of atorvastatin or rosuvastatin.

3.2 Diabetes risk

Statins increase the risk of new-onset type 2 diabetes by approximately 10% in at-risk individuals (those with pre-diabetes or metabolic syndrome). This is a class effect, more pronounced with high-intensity statins. The absolute risk increase is small (approximately 1 additional case per 200 patients treated for 4 years at high intensity). This risk is substantially outweighed by the cardiovascular benefit in patients who have an indication for statin therapy.

The appropriate clinical response to statin-associated diabetes risk: monitor fasting glucose periodically and counsel patients on lifestyle modifications -- not to stop the statin.

3.3 Memory and cognitive effects

Multiple large randomised controlled trials and systematic reviews have found no causal association between statin use and cognitive decline or dementia. The FDA added a cognitive effects label to statins in 2012 based on spontaneous reports. Subsequent evidence has not supported a causal link. The misinformation circulating about statins and memory loss is not consistent with the evidence base.

3.4 Hepatotoxicity

Statins can cause a mild, transient rise in transaminases that is clinically insignificant in the vast majority of patients. True clinical hepatotoxicity from statins is rare (approximately 1 in 100,000). Routine LFT monitoring is not recommended in patients on statins without symptoms -- the evidence does not support it.

Statins are not contraindicated in mild-to-moderate chronic liver disease. They are contraindicated in active liver disease or unexplained persistent transaminase elevation.

Section 4: Cardiovascular Risk and Treatment Thresholds

4.1 Who needs a statin

Secondary prevention (highest priority -- strong evidence): - Established atherosclerotic cardiovascular disease (prior MI, stroke, TIA, peripheral arterial disease, revascularisation) - All patients in this category should be on high-intensity statin (atorvastatin 40-80 mg or rosuvastatin 20-40 mg) regardless of baseline LDL-C

Primary prevention (evidence-based, risk-guided): - Type 2 diabetes aged over 40, or with target organ damage, or duration above 10 years: moderate-to-high intensity statin - 10-year cardiovascular risk above 10% (using validated risk calculator): statin discussion and initiation depending on shared decision - Familial hypercholesterolaemia (LDL-C above 5 mmol/L with family history of premature CVD): high-intensity statin regardless of calculated risk

4.2 LDL-C targets

The Caribbean context: Caribbean patients with type 2 diabetes and hypertension are commonly at very high cardiovascular risk by risk calculator scoring -- frequently above 10% 10-year risk. This means most Caribbean patients with these common comorbidities qualify for statin therapy under primary prevention guidelines.

4.3 Triglycerides and atherogenic dyslipidaemia

Elevated triglycerides (above 5.6 mmol/L) carry a direct risk of pancreatitis and require treatment. The main intervention is: - Restrict alcohol, refined carbohydrates, and saturated fat - Fenofibrate or bezafibrate (fibrates) - Omega-3 fatty acids at high doses (icosapentaenoic acid, EPA) have demonstrated cardiovascular benefit in the REDUCE-IT trial

For the common pattern of mildly elevated triglycerides (2-5 mmol/L) with low HDL in metabolic syndrome, lifestyle modification is first-line. Statins modestly reduce triglycerides (10-20%) and modestly raise HDL.

Section 5: Other Lipid-Lowering Drugs

5.1 Ezetimibe

Ezetimibe inhibits intestinal cholesterol absorption. It is additive to statin therapy -- combination produces approximately 25% further LDL-C reduction beyond the statin alone. IMPROVE-IT trial (2015) demonstrated that adding ezetimibe to simvastatin further reduced cardiovascular events in post-ACS patients.

Used when: LDL-C target not reached on maximum-tolerated statin; statin intolerance (ezetimibe monotherapy).

No significant drug interactions. No CYP3A4 involvement.

5.2 Fibrates

Fenofibrate, bezafibrate. Primary action: reduce triglycerides (40-60%), modestly raise HDL-C. Limited LDL-C reduction.

Key interaction: Fibrate + statin combination increases myopathy risk. Gemfibrozil (not bezafibrate or fenofibrate) is the fibrate with the highest statin interaction risk and should not be combined with statins. Fenofibrate is safer in combination with statins and is preferred when both are required.

Renal dosing: Fenofibrate requires dose reduction in CKD (Report 2); reduce dose when CrCl below 60, avoid when CrCl below 30.

5.3 PCSK9 inhibitors

Evolocumab, alirocumab. Injectable monoclonal antibodies administered every 2 or 4 weeks. Reduce LDL-C by 50-60% on top of maximally tolerated statin. Evidence from FOURIER and ODYSSEY outcomes trials demonstrates cardiovascular mortality benefit.

Caribbean context: PCSK9 inhibitors are expensive and not on Caribbean public sector formularies. They are relevant for patients with familial hypercholesterolaemia or recurrent cardiovascular events despite maximum statin and ezetimibe.

Section 6: The Statin Conversation

When a patient declines or stops statin therapy based on side effect concerns, the following framework is evidence-based:

Acknowledge the concern: side effect concerns are valid and deserve a direct response.

Separate fact from misinformation: - Muscle symptoms at standard doses without a CYP inhibitor are uncommon and can be managed by switching statin or adjusting dose - Rhabdomyolysis is rare, almost always interaction-driven, and prevented by avoiding high-risk drug combinations - The memory effect is not supported by the randomised trial evidence - The diabetes risk is real but small and outweighed by cardiovascular benefit in patients with an indication

Quantify the benefit: for a patient with established CVD (secondary prevention), high-intensity statin reduces the relative risk of a second major cardiovascular event by approximately 25-35%. In absolute terms, treating 100 high-risk patients with a statin for 5 years prevents approximately 5-6 major cardiovascular events.

Offer a practical solution: if a patient experienced muscle symptoms, switch to a lower-interaction statin (rosuvastatin or pravastatin), reduce the dose, or trial alternate-day dosing before abandoning statin therapy entirely.

Section 7: The Lipids Prescribing Checklist

Section 8: About ElesRx

ElesRx flags statin-CYP3A4 inhibitor interactions -- identifying clarithromycin, itraconazole, ciclosporin, amiodarone, diltiazem, and verapamil co-prescriptions with simvastatin and atorvastatin, and generating alerts with specific dose-cap or statin-switch recommendations. The system also flags the simvastatin 80 mg prescribing safety concern and identifies gemfibrozil-statin combinations.

The tool is available at elesrx.com. ElesRx is a product of PIPPS Smart Apps, a division of J.C. Epiphany Limited (Jamaica, est. 1998).

Section 9: Methodology and References

9.1 Data sources

Lipid-lowering drug data is drawn from the ElesRx clinical database, DailyMed, the European Medicines Agency, the European Society of Cardiology/European Atherosclerosis Society dyslipidaemia guidelines (2019), and the American College of Cardiology/American Heart Association cholesterol guidelines (2018).

9.2 Limitations

PCSK9 inhibitor prescribing in familial hypercholesterolaemia and recurrent cardiovascular disease requires specialist lipidology input. Lipoprotein(a) measurement and management, hypertriglyceridaemia-specific therapy (EPA), and LDL apheresis are beyond this report's primary scope.

9.3 Author and conflict of interest disclosure

This report was authored by Juliet Duncan, BPharm, founder of J.C. Epiphany Limited and developer of ElesRx. The author has a commercial interest in ElesRx. This report is published without an access gate as a contribution to Caribbean clinical education. No external funding was received.

9.4 Citation

Duncan J. The Lipids Report: Statins, Myopathy, and the Cholesterol Conversation in Caribbean Practice. ElesRx Clinical Reports, Report 21. Prepared June 2026. Published 2027 at elesrx.com/reports/lipids-report/. J.C. Epiphany Limited, Jamaica.

References

1. Collins R, Reith C, Emberson J, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet. 2016;388(10059):2532-2561. doi:10.1016/S0140-6736(16)31357-5

2. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes (IMPROVE-IT). N Engl J Med. 2015;372(25):2387-2397. doi:10.1056/NEJMoa1410489

3. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease (FOURIER). N Engl J Med. 2017;376(18):1713-1722. doi:10.1056/NEJMoa1615664

4. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J. 2020;41(1):111-188. doi:10.1093/eurheartj/ehz455

5. Bhatt DL, Steg PG, Miller M, et al. Cardiovascular risk reduction with icosapentaenoic acid for hypertriglyceridaemia (REDUCE-IT). N Engl J Med. 2019;380(1):11-22. doi:10.1056/NEJMoa1812792